Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1979 3
1980 2
1981 2
1983 1
1985 1
1989 5
1990 1
1991 1
1992 4
1993 4
1994 3
1995 3
1997 1
2013 2
2014 2
2016 3
2017 4
2018 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, Kalra PA, Clark R, Dargan PI, Boffito M, Sheridan R, Moran E, Darton TC, Burns F, Saralaya D, Duncan CJA, Lillie PJ, San Francisco Ramos A, Galiza EP, Heath PT, Girard B, Parker C, Rust D, Mehta S, de Windt E, Sutherland A, Tomassini JE, Dutko FJ, Chalkias S, Deng W, Chen X, Feng J, Tracy L, Zhou H, Miller JM, Das R; Study Investigators. Lee IT, et al. Among authors: dutko fj. Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19. Lancet Infect Dis. 2023. PMID: 37348519 Free article. Clinical Trial.
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, Edwards DK, Oestreicher J, Legault H, Dutko FJ, Girard B, Pajon R, Miller JM, Das R, Leav B, McPhee R. Chu L, et al. Among authors: dutko fj. Nat Med. 2022 May;28(5):1042-1049. doi: 10.1038/s41591-022-01739-w. Epub 2022 Mar 3. Nat Med. 2022. PMID: 35241844 Free PMC article. Clinical Trial.
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: dutko fj. Nat Med. 2022 Nov;28(11):2388-2397. doi: 10.1038/s41591-022-02031-7. Epub 2022 Oct 6. Nat Med. 2022. PMID: 36202997 Free PMC article. Clinical Trial.
The structure of human rhinovirus 16.
Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA, et al. Oliveira MA, et al. Among authors: dutko fj. Structure. 1993 Sep 15;1(1):51-68. doi: 10.1016/0969-2126(93)90008-5. Structure. 1993. PMID: 7915182
Crystal structure of human rhinovirus serotype 1A (HRV1A).
Kim SS, Smith TJ, Chapman MS, Rossmann MC, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA. Kim SS, et al. Among authors: dutko fj. J Mol Biol. 1989 Nov 5;210(1):91-111. doi: 10.1016/0022-2836(89)90293-3. J Mol Biol. 1989. PMID: 2555523
Drugs as molecular tools.
Dutko FJ, Baright DE, Diana GD, Fox MP, Pevear DC, McKinlay MA. Dutko FJ, et al. Adv Exp Med Biol. 1992;312:15-24. doi: 10.1007/978-1-4615-3462-4_2. Adv Exp Med Biol. 1992. PMID: 1514439 Review. No abstract available.
47 results